At the news
? NEUTRALIMPACT 3/10 8-K filed Nov 13, 2026 at 16:09 ET
Incyte announced it will not proceed with the planned Phase 3 MAESTRA-3 study of its CDK2 inhibitor INCB123667 in ovarian cancer, citing portfolio prioritization rather than safety or efficacy concerns. The company stated the decision will not affect its financial guidance or long-term outlook.
- Incyte decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, a selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in ovarian cancer.
- The study had been expected to begin in Q4 2026.
- The decision was based on prioritization of the clinical development portfolio, not on any safety or efficacy findings from the INCB123667 clinical program.
- Incyte stated the determination is not expected to affect its financial guidance or previously disclosed long-term outlook.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access